Login to Your Account



Medicare's 340B cuts pit biopharma against hospital industry

By Mari Serebrov
Regulatory Editor

Thursday, November 2, 2017

If it stands up against promised challenges, a new payment rule that would let the Centers for Medicare & Medicaid Services (CMS) cash in on some of the outpatient drug savings U.S. hospitals get through the 340B discount program could deepen the pricing rift between hospital groups and the biopharma industry.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription